46 stories mentioning UTHR
Every FINWIRES story that references UTHR, newest first.
James Edgemond, CFO and Treasurer, on April 13, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,748,802. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000009/xslF345X05/primarydocument.xml
Martine A Rothblatt, Director, Chairperson & CEO, on April 10, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,408,194. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,872 common shares of the company, with 40,513 shares held directly and 639,359 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000031/xslF345X05/primarydocument.xml
Martine A Rothblatt, Director, Chairperson & CEO, on April 09, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,489,819. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,872 common shares of the company, with 40,513 shares held directly and 639,359 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000030/xslF345X05/primarydocument.xml
James Edgemond, CFO and Treasurer, on April 09, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,778,922. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000008/xslF345X05/primarydocument.xml
United Therapeutics (UTHR) has an average rating of overweight and mean price target of $654.42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Martine A Rothblatt, Director, Chairperson & CEO, on April 08, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,514,306. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,872 common shares of the company, with 40,513 shares held directly and 639,359 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000029/xslF345X05/primarydocument.xml
Showing 41-46 of 46